The Variation in Migraine Management in Emergency Departments: Anne-Maree Kelly, MD
January 4th 2022The director of the Joseph Epstein Center for Emergency Medicine Research provided context on the types of research needed to further evaluate and improve diagnosis and management of headache in emergency departments. [WATCH TIME: 3 minutes]
Mechanical Thrombectomy Shows Functional Benefit for Large Vessel Occlusion
January 4th 2022Favorable outcome, defined as modified Rankin Scores of 0-2, was achieved in patients presenting with ASPECTS of 2-5 regardless of treatment with mechanical thrombectomy in the early or extended windows.
Understanding Cognitive Decline Based on Multiple Sclerosis Phenotype: Dejan Jakimovski, MD, PhD
January 4th 2022The research assistant professor at the Buffalo Neuroimaging Analysis Center provided context on how different forms of multiple sclerosis impact cognitive decline in patients. [WATCH TIME: 3 minutes]
Antiseizure Medications Display Mortality Differences in Poststroke Epilepsy
January 4th 2022The study authors concluded that while there are differences in survival between specific ASMs, lamotrigine and levetiracetam appear to be reasonable first-line treatment options for patients with poststroke epilepsy.
Differentiating Diet Approaches in Multiple Sclerosis: Mona Bostick, RDN, LDN, MSCS
January 3rd 2022The founder of MS Bites discussed the role dietitians can play in care of patients with MS, noting that they have not historically been included in the comprehensive care team, and differentiating their approaches to care. [WATCH TIME: 2 minutes]
Preventing TSC By Treating at the Earliest Stage: Darcy Krueger, MD, PhD
January 3rd 2022The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the thought behind STOPS2, a trial aimed at preventing or delaying seizure onset in tuberous sclerosis complex. [WATCH TIME: 3 minutes]
The Effect of Efgartigimod’s Approval on the Myasthenia Gravis Landscape: James F. Howard, MD
December 29th 2021The Distinguished Professor of Neuromuscular Disease at University of North Carolina School of Medicine offered his insight into the newly approved Argenx agent, marketed as Vyvgart. [WATCH TIME: 3 minutes]